IP Library Granted Patent US 11,351,118
Granted Patent B2
US 11,351,118 · App. 16/470,490 · Granted Jun 7, 2022

Methods for ameliorating infusion reactions

Inventors: Jeffrey P. Bechard (Surrey, CA); Wayne J. Wallis (Seattle, WA)
Assignee: ARBUTUS BIOPHARMA CORPORATION
A61K9/127A61K9/0019A61K31/192A61K47/10A61K47/24A61P29/00C12N15/111A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,351,118
App. No.
16/470,490
Granted
Jun 7, 2022
Kind
B2
Abstract

Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.

Claims (14)

1. A method of ameliorating an infusion reaction associated with intravenous administration of at least one lipid formulated therapeutic agent in a mammal in need thereof, comprising administering to the mammal via injection a therapeutically effective amount of a nonsteroidal anti-inflammatory (NSAID) prior to the at least one lipid formulated therapeutic agent being intravenously administered, wherein the NSAID is ketorolac, wherein the infusion reaction comprises hypertension followed by hypotension and an increase in plasma thromboxane B2 levels, wherein the at least one lipid formulated therapeutic agent is formulated in a lipid nanoparticle (LNP), and wherein the lipid formulated therapeutic agent is a nucleic acid.

2. The method of claim 1 , wherein the administration of the NSAID begins within about 2 hours prior to the administration of the at least one lipid formulated therapeutic agent.

3. The method of claim 1 , wherein the ketorolac is administered in a dose of about 15 mg to about 60 mg.

4. The method of claim 3 , wherein the ketorolac is administered in a dose of about 30 mg to about 60 mg.

5. The method of claim 1 , wherein the at least one lipid formulated therapeutic agent is formulated in a lipid nanoparticle (LNP) comprising:

a) the at least one therapeutic agent;

b) a cationic lipid; and

C) a non-cationic lipid.

6. The method of claim 1 , wherein the lipid formulated therapeutic agent is siRNA or mRNA.

7. The method of claim 6 , wherein the lipid formulated therapeutic agent is siRNA.

8. The method of claim 6 , wherein the lipid formulated therapeutic agent is mRNA.

9. The method of claim 5 , further comprising administering an additional therapeutic agent.

10. The method of claim 9 , wherein the additional therapeutic agent is dexamethasone.

11. The method of claim 1 , wherein the NSAID is administered parenterally, intravenously, intramuscularly or subcutaneously.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Aug 31, 2020
From: PROTIVA BIOTHERAPEUTICS, INC.; ARBUTUS BIOPHARMA CORPORATION
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 053641/0534 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2020
From: BECHARD, JEFFREY P.; WALLIS, WAYNE J.
To: PROTIVA BIOTHERAPEUTICS, INC.
Reel/Frame 053579/0827 →
Continuity (2)
Provisional Application 62437537 · Dec 21, 2016
Related Publication 20190328664A1 · Oct 31, 2019